Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

Inclusion Criteria: * Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures). * Age ≥ 18 years old and ≤ 75 years old at the time of randomization. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Expected life expectancy of at least 3 months. * Histologically or cytologically confirmed diagnosis of NSCLC. * Locally advanced or metastatic NSCLC (American Joint Committee on Cancer \[AJCC\] 8th edition). * Previously received systemic platinum-based chemotherapy and PD-1/L1 inhibitors. * At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. * Adequate organ function. Exclusion Criteria: * Histologic or cytopathologic evidence of the presence of small cell lung carcinoma. * Other malignancies within 3 years prior to randomization. * Known actionable genomic alterations. * Prior administration of any immunotherapy targeting immune mechanisms other than PD-1/PD-L1 inhibitors. * Previous treatment with docetaxel. * History of severe bleeding tendency or coagulation dysfunction. * Active autoimmune disease requiring systemic therapy within 2 years prior to randomization. * History of myocarditis, cardiomyopathy, and malignant arrhythmia.